[go: up one dir, main page]

Lenka et al., 2022 - Google Patents

Tics and Tourette's syndrome.

Lenka et al., 2022

Document ID
3796078367780964003
Author
Lenka A
Jankovic J
Publication year
Publication venue
Movement Disorders in Psychiatry

External Links

Snippet

Tourette's syndrome (TS), also known as Gilles de la Tourette syndrome, is a complex childhood-onset neurobehavioral disorder. The cardinal symptom of TS is a tic, which is defined as sudden-onset, recurrent, brief-lasting, irregular, involuntary movement (motor tic) …
Continue reading at books.google.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Similar Documents

Publication Publication Date Title
Singer Tics and Tourette syndrome
Da Silva et al. An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder
Krueger et al. Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
Dam et al. The role of the gut-brain axis in attention-deficit/hyperactivity disorder
Anagnostou et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth
Aldenkamp et al. Randomized double‐blind parallel‐group study comparing cognitive effects of a low‐dose lamotrigine with valproate and placebo in healthy volunteers
Tan Mood disorders in Parkinson's disease
Kelly et al. High-intensity exercise acutely increases substantia nigra and prefrontal brain activity in Parkinson’s disease
Dubrovsky et al. Expanding the phenotype of late‐onset pompe disease: tongue weakness: a new clinical observation
Bruxel et al. ADHD pharmacogenetics across the life cycle: new findings and perspectives
Zuddas et al. Attention-deficit/hyperactivity disorder: a neuropsychiatric disorder with childhood onset
Summers et al. Does levodopa improve vision in albinism? Results of a randomized, controlled clinical trial
Litvan Atypical parkinsonian disorders
Pascual‐Morena et al. Global prevalence of intellectual developmental disorder in dystrophinopathies: A systematic review and meta‐analysis
Nakamura et al. Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression
Lagas et al. The Effect of Combined Patching and Citalopram on Visual Acuity in Adults with Amblyopia: A Randomized, Crossover, Placebo‐Controlled Trial
Reghunandanan et al. Obsessive-compulsive and related disorders
Gołąb-Janowska et al. Risk factors of fatigue in idiopathic Parkinson’s disease in a Polish population
Swain et al. Tourette syndrome and tic disorders: overview and practical guide to diagnosis and treatment
Lenka et al. Tics and Tourette’s syndrome.
Mikos et al. Stability of neuropsychological performance in anorexia nervosa
WO2025064229A1 (en) Methods of treating a cognitive impairment
Ghosh et al. Tourette Syndrome: An Update
Noyce et al. Parkinson’s disease: basic pathomechanisms and a clinical overview
Tochen et al. Tics and Tourette Syndrome